

Robert P Giugliano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9149405/robert-p-giugliano-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

439
papers

32,612
citations

77
h-index

174
g-index

464
ext. papers

39,578
ext. citations

8.7
avg, IF

7.05
L-index

#	Paper	IF	Citations
439	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
438	Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.. <i>Journal of the American Heart Association</i> , 2022 , e022733	6	1
437	Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, e153	15.1	
436	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.. <i>Advances in Therapy</i> , 2022 , 39, 1832	4.1	0
435	Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation.. <i>European Heart Journal Supplements</i> , 2022 , 24, A1-A10	1.5	0
434	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. <i>Journal of the American Heart Association</i> , 2022 , e022937	6	3
433	Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS121011382	6	1
432	Acute coronary syndromes.. <i>Lancet, The</i> , 2022 , 399, 1347-1358	40	7
431	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.. <i>PLoS ONE</i> , 2022 , 17, e0266615	3.7	0
430	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239,234 Patients During 2005 to 2018 in the United States.. <i>Journal of the American Heart Association</i> , 2022 , e022198	6	3
429	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1660-1671	15.1	7
428	Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. <i>JAMA Cardiology</i> , 2021 ,	16.2	7
427	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1499-1507	15.1	4
426	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1525-1537	15.1	6
425	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021 , 144, 1845-1855	16.7	10
424	Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2021 , 42, 1698-1708	9.5	11
423	Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1197-1207	15.1	10

422	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. <i>Journal of Clinical Neuroscience</i> , 2021 , 86, 294-300	2.2	3
421	Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. <i>Circulation Journal</i> , 2021 , 85, 2063-2070	2.9	1
420	Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. <i>American Heart Journal</i> , 2021 , 235, 132-139	4.9	0
419	Myocardial Infarction and Evolocumab-Reply. <i>JAMA Cardiology</i> , 2021 , 6, 1222-1223	16.2	
418	Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3232-3233	15.1	0
417	Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. <i>Circulation</i> , 2021 , 144, 249-251	16.7	0
416	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. <i>Circulation</i> , 2021 , 143, 33-44	16.7	25
415	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 139-147	16.2	16
414	Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58634 patients across four randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f40-f49	6.4	5
413	Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 259-267	15.1	5
412	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021 , 143, 470-478	16.7	13
411	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation) Investigators. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 , 46, 103-111	4.9	2
410	Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 140-149	7	8
409	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , 2021 , 143, 685-695	16.7	3
408	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003006	5.2	1
407	Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance". <i>Drug Safety</i> , 2021 , 44, 503-504	5.1	2
406	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021 , 143, 673-684	16.7	2
405	Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. <i>Circulation</i> , 2021 , 144, 1732-1734	16.7	2

404	A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 634-636	15.1	1
403	Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. <i>JAMA Cardiology</i> , 2021 , 6, 1342-1343	16.2	
402	Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. <i>European Heart Journal</i> , 2021 ,	9.5	5
401	Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. <i>International Journal of General Medicine</i> , 2021 , 14, 6277-6286	2.3	14
400	Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 281-282	3.8	1
399	Association of APOE genotype and lipid lowering with cognitive function in a randomized placebo-controlled trial of Evolocumab. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047188	1.2	
398	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006511	5.8	1
397	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 1637-1643	40	62
396	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. <i>JACC: CardioOncology</i> , 2020 , 2, 385-396	3.8	0
395	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020 , 5, 709-713	16.2	25
394	Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 787-793	16.2	11
393	Cognition After Lowering LDL-Cholesterol With Evolocumab. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2283-2293	15.1	28
392	Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. <i>American Journal of Cardiology</i> , 2020 , 127, 176-183	3	8
391	Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. <i>Cardiology and Therapy</i> , 2020 , 9, 1-4	2.8	1
390	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , 2020 , 141, 1600-1607	16.7	32
389	Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. <i>Clinical Cardiology</i> , 2020 , 43, 684-690	3.3	3
388	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 835-837	15.1	
387	What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. <i>Cardiology and Therapy</i> , 2020 , 9, 59-73	2.8	8

386	Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 289-300	15.1	12
385	Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2020 , 304, 185-191	3.2	13
384	LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320902750	3.9	22
383	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. <i>Global Cardiology Science & Practice</i> , 2020 , 2020, e202039	0.7	1
382	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 167-175	6.4	5
381	Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. <i>Circulation</i> , 2020 , 141, 616-623	16.7	61
380	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. <i>Circulation</i> , 2020 , 141, 367-375	16.7	67
379	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Registry in Acute Coronary SyndromEs). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 284-292	4.6	3
378	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. <i>Stroke</i> , 2020 , 51, 1546-1554	6.7	35
377	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. <i>International Journal of Cardiology</i> , 2020 , 317, 159-166	3.2	0
376	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. <i>JAMA Cardiology</i> , 2020 ,	16.2	4
375	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. <i>JAMA Cardiology</i> , 2020 , 5, 952-957	16.2	22
374	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. <i>Circulation</i> , 2019 , 140, 1308-1317	16.7	85
373	Cardiology and Therapy: A Summary of 2018 and Key Areas of Emerging Research in 2019. <i>Cardiology and Therapy</i> , 2019 , 8, 1-3	2.8	
372	Correctly understanding the diabetes data in FOURIER. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2342-2343		
371	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2961-2970	15.1	59
370	Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. <i>JAMA Cardiology</i> , 2019 , 4, 613-619	16.2	41
369	Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. <i>JAMA Cardiology</i> , 2019 , 4, 600-601	16.2	

368	Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1336-1349	15.1	56
367	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 217-224	5.1	3
366	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 176-185	4.3	13
365	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1057-1068	15.1	21
364	Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. <i>Hypertension</i> , 2019 , 74, 597-605	8.5	6
363	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 846-854	16.2	40
362	Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 179-189	15.1	21
361	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2132-2146	15.1	58
360	Reply: Anticoagulants in Atrial Fibrillation and Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2436-2437	15.1	
359	Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2019 , 140, 1792-1801	16.7	8
358	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019 , 21, 1571-1579	12.3	21
357	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019 , 18, 66-71	1.3	14
356	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 3013-3022	15.1	30
355	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019 , 40, 1518-1527	9.5	34
354	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019 , 40, 1492-1500	9.5	31
353	Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Circulation</i> , 2019 , 139, 760-771	16.7	54
352	Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. <i>Europace</i> , 2019 , 21, 306-312	3.9	3
351	Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. <i>European Heart Journal</i> , 2019 , 40, 1541-1550	9.5	53

350	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005041	5.8	8
349	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. <i>Ageing Research Reviews</i> , 2019 , 49, 115-124	12	15
348	The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 554-561	4.3	7
347	Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. <i>JAMA Cardiology</i> , 2019 , 4, 59-63	16.2	24
346	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019 , 139, 1483-1492	16.7	288
345	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. <i>Circulation</i> , 2018 , 138, 756-766	16.7	136
344	Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2018 , 257, 102-107	3.2	14
343	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation</i> , 2018 , 137, 1571-1582	16.7	198
342	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1001-1008	7	11
341	Inflammatory and Cholesterol Risk in the FOURIER Trial. <i>Circulation</i> , 2018 , 138, 131-140	16.7	127
340	Clinical benefits of evolocumab appear less than hoped - Authors' reply. <i>Lancet, The</i> , 2018 , 391, 934-935	40	2
339	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. <i>JAMA Cardiology</i> , 2018 , 3, 823-828	16.2	102
338	PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 835-843	4.9	5
337	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2162-2175	15.1	83
336	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
335	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e003998	5.8	20
334	The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 435-442	3.9	3
333	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". <i>Circulation</i> , 2018 , 137, 2662-2663	16.7	

332	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. <i>JAMA Cardiology</i> , 2018 , 3, 749-753	16.2	66
331	Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1013-1019	4	
330	Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018 , 27, 857-864	2.8	2
329	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). <i>Circulation</i> , 2018 , 137, 338-350	16.7	348
328	Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?. <i>Circulation</i> , 2018 , 138, 1356-1365	16.7	22
327	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 934-943	18.1	58
326	Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1466-1475	15.1	8
325	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018 , 39, 3810-3820	9.5	18
324	Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e008987	6	59
323	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , 2018 , 270, 245-252	3.2	34
322	Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 423-432	2.6	7
321	Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement. <i>Cardiology and Therapy</i> , 2018 , 7, 71-77	2.8	2
320	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2018 , 138, 1963-1973	16.7	23
319	Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. <i>International Journal of Cardiology</i> , 2017 , 232, 264-270	3.2	5
318	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. <i>European Heart Journal</i> , 2017 , 38, 888-896	9.5	29
317	Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Heart Rhythm</i> , 2017 , 14, 599-605	6.7	5
316	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017 , 10,	6.4	94
315	Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 442-448	16.2	39

314	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , 2017 , 2, 556-560	16.2	15
313	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 911-921	15.1	111
312	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017 , 135, 1273-1275	16.7	94
311	Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. <i>Clinical Cardiology</i> , 2017 , 40, 59-65	3.3	38
310	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017 , 130, 1170-1176	2.4	6
309	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation: Cardiovascular Quality & Outcomes</i> , 2017 , 10,	5.8	7
308	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. <i>Value in Health Regional Issues</i> , 2017 , 12, 74-83	1.6	6
307	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 214-220	6.4	0
306	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1372-1382	15.1	87
305	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1363-1371	15.1	84
304	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. <i>JAMA Cardiology</i> , 2017 , 2, 547-555	16.2	92
303	Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. <i>JAMA Cardiology</i> , 2017 , 2, 598-607	16.2	97
302	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
301	Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. <i>Clinical Cardiology</i> , 2017 , 40, 155-162	3.3	29
300	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation</i> , 2017 , 136, 2440-2450	16.7	67
299	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017 , 2, 1069-1078	16.2	91
298	Reply: Ezetimibe, Risk Stratification, and Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1200	15.1	1
297	Evolocumab in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 787-8	59.2	21

296	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 941-950	18.1	330
295	Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	8
294	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	14
293	Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. <i>JAMA Cardiology</i> , 2017 , 2, 935-936	16.2	16
292	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017 , 377, 633-643	59.2	263
291	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Journal of the American Heart Association</i> , 2017 , 6,	6	28
290	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017 , 377, 1997	59.2	17
289	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 1385-1391	16.2	62
288	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. <i>Journal of the Formosan Medical Association</i> , 2017 , 116, 591-598	3.2	5
287	Major Bleeding in Patients With Diabetes and Atrial Fibrillation Treated With New Oral Anticoagulants-Reply. <i>JAMA Cardiology</i> , 2017 , 2, 1168	16.2	3
286	First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. <i>International Journal of Cardiology</i> , 2017 , 244, 192-195	3.2	17
285	Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	25
284	Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. <i>Lancet, The</i> , 2017 , 390, 1962-1971	40	336
283	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. <i>European Heart Journal</i> , 2016 , 37, 3576-3584	9.5	55
282	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	79
281	Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation. <i>American Journal of Cardiology</i> , 2016 , 118, 1419-1426	3	9
280	Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 625-31	3	6
279	Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. <i>Circulation Journal</i> , 2016 , 80, 860-9	2.9	64

278	Updates on Acute Coronary Syndrome: A Review. <i>JAMA Cardiology</i> , 2016 , 1, 718-30	16.2	70
277	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016 , 134, 248-61	16.7	82
276	Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2016 , 134, 24-36	16.7	174
275	Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 3025-6	15.1	1
274	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016 , 129, 1117-1123.e2	2.4	12
273	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2888-99	15.1	117
272	Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 353-361	15.1	137
271	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 171, 25-32	4.9	10
270	Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. <i>American Journal of Medicine</i> , 2016 , 129, 850-857.e2	2.4	40
269	Rationale and design of the Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. <i>American Heart Journal</i> , 2016 , 173, 94-101	4.9	124
268	EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016 , 37, 1296-303	9.5	87
267	Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1117-1123.e2	4.9	13
266	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. <i>International Journal of Cardiology</i> , 2016 , 203, 708-13	3.2	2
265	Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines. <i>Cardiology in Review</i> , 2016 , 24, 170-6	3.2	2
264	Reply: Personalize and Optimize Lipid-Lowering Therapies. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 326	15.1	3
263	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 2144-2153	59.2	418
262	Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors. <i>Current Opinion in Cardiology</i> , 2016 , 31, 644-653	2.1	4
261	Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	42

260	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". <i>Circulation</i> , 2016 , 133, e463	16.7	
259	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 472-89	4.9	154
258	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	144
257	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016 , 133, 1560-73	16.7	15
256	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016 , 129, S1-S29	2.4	19
255	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. <i>Journal of Lipid Research</i> , 2016 , 57, 1086-96	6.3	138
254	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 537-44	5.8	22
253	Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. <i>Heart Rhythm</i> , 2016 , 13, 2340-2347	6.7	23
252	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1169-1178	15.1	99
251	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. <i>JACC: Heart Failure</i> , 2016 , 4, 870-880	7.9	41
250	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1289-97	27.4	614
249	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016 , 182, 89-96	4.9	13
248	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 1019-34	3.1	7
247	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 999-1006	16.2	45
246	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. <i>International Journal of Stroke</i> , 2016 , 11, 950-967	6.3	2
245	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 3425-3435	4	12
244	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). <i>Stroke</i> , 2016 , 47, 2075-82	6.7	57
243	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <i>International Journal of Cardiology</i> , 2016 , 222, 615-619	3.2	4

242	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <i>European Journal of Heart Failure</i> , 2016 , 18, 1153-61	12.3	59
241	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016 , 39, 345-6	3.3	46
240	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015 , 385, 2280-7	40	126
239	Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2638-2651	15.1	123
238	Influence of proven oral therapies in the very old with acute coronary syndromes: A 15 year experience. <i>International Journal of Cardiology</i> , 2015 , 198, 213-5	3.2	1
237	Editors' Picks for 2014 and a Look into the Future. <i>Cardiology and Therapy</i> , 2015 , 4, 1-3	2.8	
236	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1500-9	59.2	1081
235	Practical management of anticoagulation in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1340-1360	15.1	67
234	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 357-67	5.8	26
233	Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. <i>American Heart Journal</i> , 2015 , 170, 668-74	4.9	14
232	Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. <i>Circulation</i> , 2015 , 132, 1224-33	16.7	189
231	Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience. <i>Cardiology and Therapy</i> , 2015 , 4, 197-201	2.8	10
230	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 129-38	5.1	2
229	Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial. <i>Circulation Journal</i> , 2015 , 79, 2560-7	2.9	29
228	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015 , 372, 2387-97	59.2	2371
227	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , 2015 , 36, 1470-7	9.5	42
226	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015 , 385, 2288-95	40	275
225	Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 97-106	6.4	13

224	Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. <i>Clinical Cardiology</i> , 2015 , 38, 230-5	3.3	14
223	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <i>American Heart Journal</i> , 2015 , 170, 1140-50	4.9	22
222	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Hospital Practice (1995)</i> , 2015 , 43, 258-67	2.2	2
221	A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 15-28	6.4	11
220	Abstract 16708: Increasing Age and the Benefit From Higher-intensity Lipid Lowering With Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial. <i>Circulation</i> , 2015 , 132,	16.7	1
219	Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. <i>American Journal of Cardiovascular Drugs</i> , 2014 , 14, 111-27	4	17
218	Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. <i>Heart</i> , 2014 , 100, 396-405	5.1	51
217	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014 , 383, 955-62	40	2823
216	The year in acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 201-14	15.1	13
215	Edoxaban: Review of pharmacology and key phase I to III clinical trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 409-16	2.6	17
214	New oral anticoagulants in patients with atrial fibrillation - Authors' reply. <i>Lancet, The</i> , 2014 , 384, 25-6	40	12
213	Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 576-84	15.1	35
212	Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1297-305	3	8
211	Genotype-guided dosing of warfarin. <i>Clinical Chemistry</i> , 2014 , 60, 920-2	5.5	8
210	Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. <i>Clinical Chemistry</i> , 2014 , 60, 158-64	5.5	59
209	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014 , 168, 205-12.e1	4.9	83
208	AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction	15.1	42
207	The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 526-32	2.6	2

206	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. <i>Circulation</i> , 2014 , 129, 234-43	16.7	180
205	Do diabetic patients with acute coronary syndromes have a higher threshold for ischemic pain?. <i>Arquivos Brasileiros De Cardiologia</i> , 2014 , 103, 183-91	1.2	1
204	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. <i>European Heart Journal</i> , 2014 , 35, 2249-59	9.5	106
203	Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. <i>European Heart Journal</i> , 2014 , 35, 1457-65	9.5	130
202	Perioperative management of target-specific oral anticoagulants. <i>Hospital Practice (1995)</i> , 2014 , 42, 38-45	4.5	3
201	Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTEMI) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTEMI-ACS (EARLY-ACS) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 84, 224-32	2.7	3
200	Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. <i>Clinical Cardiology</i> , 2014 , 37, 160-6	3.3	3
199	Target-specific oral anticoagulants: practice issues for the clinician. <i>Hospital Practice (1995)</i> , 2014 , 42, 48-61	2.2	1
198	Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. <i>Stroke</i> , 2014 , 45, 2372-8	6.7	43
197	Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 37-45	4.3	47
196	Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 656-63	5.8	18
195	Coronary artery stents: advances in technology. <i>Hospital Practice (1995)</i> , 2014 , 42, 83-91	2.2	8
194	Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2014 , 168, 182-8.e1	4.9	10
193	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1278-1288	15.1	266
192	Emerging antithrombotic drugs for acute coronary syndrome. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 307-18	3.7	1
191	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 115-30	5.1	
190	Cardiac sarcoidosis: case report, workup, and review of the literature. <i>Cardiology and Therapy</i> , 2013 , 2, 181-97	2.8	
189	Dabigatran excess: case report and review of the literature. <i>Cardiology and Therapy</i> , 2013 , 2, 111-24	2.8	7

188	Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. <i>American Heart Journal</i> , 2013 , 166, 723-8	4.9	20
187	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2013 , 369, 2093-104	59.2	3215
186	Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. <i>Clinical Cardiology</i> , 2013 , 36, 61-7	3.3	61
185	Acute dissection of the descending aorta: a case report and review of the literature. <i>Cardiology and Therapy</i> , 2013 , 2, 199-213	2.8	7
184	Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013 , 165, 302-7.e1	4.9	65
183	Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. <i>American Heart Journal</i> , 2013 , 165, 583-590.e1	4.9	18
182	NonST-Segment Elevation Acute Coronary Syndromes 2013 , 153-177		
181	Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 242-251	15.1	29
180	Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1461-3	15.1	1
179	Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2013 , 165, 918-925.e2	4.9	63
178	Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. <i>International Journal of Cardiology</i> , 2013 , 167, 2580-7	3.2	11
177	Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 199-210	2.6	1
176	Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2013 , 166, 466-73	4.9	2
175	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013 , 168, 2510-7	3.2	14
174	Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. <i>International Journal of Cardiology</i> , 2013 , 167, 548-54	3.2	8
173	The relationship between meteorological conditions and index acute coronary events in a global clinical trial. <i>International Journal of Cardiology</i> , 2013 , 168, 2315-21	3.2	11
172	Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 290	6	2
171	The P-glycoprotein transport system and cardiovascular drugs. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2495-502	15.1	243

170	Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology. <i>European Heart Journal</i> , 2013 , 34, 2031-3	9.5	7
169	Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 555-9	2.6	12
168	Response to letter regarding article, Sustained ventricular tachycardia and ventricular fibrillation complicating nonST-segment elevation acute coronary syndromes <i>Circulation</i> , 2013 , 127, e634	16.7	0
167	Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines-Coronary Artery Disease program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 4, e10	5.8	21
166	AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57	16.7	139
165	Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. <i>Clinical Cardiology</i> , 2013 , 36, 222-7	3.3	17
164	Cholesterol levels and the association of statins with in-hospital mortality of myocardial infarction patients insights from a Chilean registry of myocardial infarction. <i>Clinical Cardiology</i> , 2013 , 36, 305-11	3.3	1
163	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. <i>Lancet, The</i> , 2012 , 380, 2007-17	40	327
162	Letter from the editor. <i>Cardiology and Therapy</i> , 2012 , 1, 1	2.8	
161	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2127-39	15.1	11
160	Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. <i>Chronobiology International</i> , 2012 , 29, 1390-6	3.6	12
159	Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. <i>International Journal of Cardiology</i> , 2012 , 155, 424-9	3.2	9
158	Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 927-35	5	17
157	Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2296-304	15.1	23
156	Can we predict outcomes in atrial fibrillation?. <i>Clinical Cardiology</i> , 2012 , 35 Suppl 1, 10-4	3.3	15
155	Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. <i>Clinical Cardiology</i> , 2012 , 35, 385-91	3.3	37
154	Bridging therapy after recent stent implantation: case report and review of data. <i>Cardiovascular Revascularization Medicine</i> , 2012 , 13, 30-8	1.6	9
153	In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups. <i>Diabetes Care</i> , 2012 , 35, 150-2	14.6	10

152	Management of non-ST-segment elevation acute coronary syndrome: comparison of the updated guidelines from North America and Europe. <i>Critical Pathways in Cardiology</i> , 2012 , 11, 62-73	1.3	
151	Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 205-13	5.8	34
150	Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. <i>Circulation</i> , 2012 , 126, 41-9	16.7	55
149	Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 925-36	7	112
148	Importance of dose selection in novel oral anticoagulants for atrial fibrillation. <i>Archivos De Cardiologia De Mexico</i> , 2012 , 82, 308-11	0.2	1
147	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2342-54	15.1	6
146	Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. <i>American Heart Journal</i> , 2011 , 162, 884-892.e1	4.9	7
145	ED to catheterization laboratory: a roundtable integrating trials with practice. <i>American Journal of Emergency Medicine</i> , 2011 , 29, 1203-16	2.9	
144	Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy. <i>Coronary Artery Disease</i> , 2011 , 22, 100-12	1.4	
143	Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy. <i>Coronary Artery Disease</i> , 2011 , 22, 113-21	1.4	
142	Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion. <i>Journal of Interventional Cardiology</i> , 2011 , 24, 119-36	1.8	2
141	Effectiveness and safety of percutaneous coronary intervention after fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2011 , 107, 1001-9	3	5
140	Dabigatran: a review of clinical and pharmacoeconomic evidence. <i>Critical Pathways in Cardiology</i> , 2011 , 10, 117-27	1.3	11
139	Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. <i>Circulation</i> , 2011 , 123, 722-30	16.7	33
138	Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. <i>Critical Pathways in Cardiology</i> , 2011 , 10, 93-8	1.3	57
137	Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011 , 4, 448-58	5.8	25
136	Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). <i>Circulation</i> , 2011 , 123, 2681-9	16.7	134
135	The facts behind niacin. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011 , 5, 227-40	3.4	16

134	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. <i>Future Cardiology</i> , 2011 , 7, 459-70	1.3	13
133	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i> , 2010 , 121, 1868-77	16.7	94
132	Perspectives on the 2009 focused updates on the management of ST-segment elevation myocardial infarction and percutaneous intervention. <i>Critical Pathways in Cardiology</i> , 2010 , 9, 126-33	1.3	1
131	Lipid lowering goals: back to nature?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 185-91	3.4	12
130	One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010 , 31, 2097-102	9.5	5
129	Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010 , 31, 2103-10	9.5	33
128	Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1885-94	15.1	47
127	Prior aspirin use and outcomes in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1376-85	15.1	30
126	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 2126-38	15.1	4
125	Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2010 , 159, 55-62	4.9	6
124	Novel biomarkers in cardiovascular disease: update 2010. <i>American Heart Journal</i> , 2010 , 160, 583-94	4.9	115
123	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). <i>American Heart Journal</i> , 2010 , 160, 685-91	4.9	377
122	Antithrombotics in acute coronary syndromes: updates from the past year. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010 , 12, 84-99	2.1	1
121	Day 1 care in patients with non-ST-segment elevation myocardial infarction. <i>Cardiovascular Revascularization Medicine</i> , 2010 , 11, 41-51	1.6	1
120	Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 806-11	5	60
119	Clinical problem-solving. When past is prologue. <i>New England Journal of Medicine</i> , 2009 , 360, 1016-22	59.2	3
118	Early versus delayed, provisional eptifibatide in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 360, 2176-90	59.2	396
117	ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 1-10	5.1	3

116	Glycoprotein IIb/IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. <i>Journal of Emergency Medicine</i> , 2009 , 36, 162-70	1.5	1
115	Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. <i>American Heart Journal</i> , 2009 , 157, 673-9.e1	4.9	25
114	Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. <i>American Heart Journal</i> , 2009 , 158, 695-705	4.9	12
113	Antithrombotics in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 969-84	15.1	44
112	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1544-55	15.1	5
111	Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. <i>Drugs</i> , 2009 , 69, 1433-43	12.1	7
110	Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e417-21	3.8	9
109	Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. <i>Critical Pathways in Cardiology</i> , 2009 , 8, 12-9	1.3	3
108	Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. <i>Fundamental and Clinical Cardiology</i> , 2009 , 19-36		
107	Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 914-20	15.1	53
106	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1095-103	15.1	7
105	The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008 , 131, 105-12	3.2	2
104	Rationale and design of IMPROVE-IT (IMPROved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 156, 826-32	4.9	240
103	Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization. <i>American Journal of Cardiovascular Drugs</i> , 2008 , 8, 187-97	4	2
102	Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 51, 425-33	3.1	4
101	Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. <i>Journal of Interventional Cardiology</i> , 2008 , 21, 222-33	1.8	2
100	Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2398-407	15.1	63
99	Non ST-Elevation Acute Coronary Syndromes 2007 , 221-245		

98	Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation. <i>Journal of Nuclear Cardiology</i> , 2007 , 14, 53-8	2.1	13
97	Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2007 , 100, 1734-8	3	19
96	A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. <i>European Heart Journal</i> , 2007 , 28, 2070-6	9.5	7
95	Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond. <i>Future Cardiology</i> , 2007 , 3, 365-75	1.3	3
94	The year in non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1386-95	15.1	3
93	Inhibition of tissue factor as a novel approach to anticoagulation in patients with coronary artery disease. <i>Future Cardiology</i> , 2006 , 2, 85-91	1.3	1
92	The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 37-42	15.1	53
91	The year in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 386-95	15.1	4
90	Comparison of long-term mortality across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , 2006 , 151, 1065-71	4.9	67
89	Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 315-22	2.3	19
88	Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 119-29	5.1	26
87	The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatid in the treatment of patients with non-ST-segment elevation acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 221-30	4.9	75
86	Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 321-3	15.1	26
85	Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 357-62	15.1	11
84	U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 178-80	15.1	125
83	The year in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 906-19	15.1	30
82	Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 228-33	3	3
81	Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 224-7	3	2

80	Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2005 , 95, 337-42	3	4
79	Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 383-6	3	20
78	Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). <i>American Journal of Cardiology</i> , 2005 , 95, 611-4	3	21
77	Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2005 , 96, 773-7	3	19
76	Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2005 , 352, 1646-54	59.2	236
75	2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 114-5		10
74	Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. <i>Circulation</i> , 2005 , 111, 2042-9	16.7	487
73	Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. <i>European Heart Journal</i> , 2004 , 25, 1998-2005	9.5	109
72	Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. <i>Circulation</i> , 2004 , 110, 679-84	16.7	43
71	Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , 2004 , 110, 500-6	16.7	144
70	Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.	16.7	53
69	Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2004 , 25, 1702-10	9.5	24
68	The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004 , 25, 1139-45	9.5	15
67	Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 93, 1218-22	3	37
66	Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. <i>American Journal of Cardiology</i> , 2004 , 93, 1362-7, A5-6	3	36
65	Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 108-11	3	4
64	Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. <i>American Journal of Cardiology</i> , 2004 , 94, 178-81	3	9
63	Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 1113-7	3	6

62	Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 1406-10	3	27
61	Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 17, 177-84	5.1	23
60	Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 549-56	15.1	24
59	Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1170-6	15.1	6
58	Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 783-9	15.1	19
57	Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 980-7	15.1	38
56	Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. <i>American Heart Journal</i> , 2004 , 147, 847-52	4.9	22
55	Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. <i>American Heart Journal</i> , 2004 , 148, 336-40	4.9	61
54	Baseline troponin in acute coronary syndromes managed invasively. <i>American Journal of Medicine</i> , 2004 , 117, 963-5	2.4	
53	Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: A simple index that predicts mortality in ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 783-789	15.1	74
52	Low-molecular-weight heparins for the treatment of acute coronary syndromes. <i>Seminars in Vascular Medicine</i> , 2003 , 3, 391-402		3
51	Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 331-42	27.4	65
50	Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. <i>Journal of Thrombosis and Thrombolysis</i> , 2003 , 15, 189-96	5.1	39
49	The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2003 , 16, 167-74	5.1	18
48	Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 92, 1155-9	3	28
47	Meta-analysis of corticosteroid treatment in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 91, 1055-9	3	132
46	Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 92, 595-7	3	18
45	Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). <i>American Journal of Cardiology</i> , 2003 , 92, 598-600	3	15

44	Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1535-43	15.1	215
43	Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1251-60	15.1	80
42	Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 7-16	15.1	130
41	Improving antithrombotic treatment in patients after myocardial infarction. <i>Lancet, The</i> , 2003 , 362, 757	40	1
40	Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. <i>Circulation</i> , 2003 , 108, 2828-30	16.7	63
39	Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Reteplase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 71-7	15.1	119
38	Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. <i>American Heart Journal</i> , 2002 , 143, 966-70	4.9	25
37	Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. <i>American Heart Journal</i> , 2002 , 144, 1003-11	4.9	82
36	Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction. <i>Cardiology</i> , 2001 , 1, 5-13		11
35	Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2001 , 88, 353-8	3	42
34	Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). <i>American Journal of Cardiology</i> , 2001 , 88, 831-6	3	43
33	Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. <i>American Heart Journal</i> , 2001 , 141, 742-50	4.9	54
32	A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. <i>Lancet, The</i> , 2001 , 358, 1571-5	40	207
31	ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. <i>American Journal of Cardiology</i> , 2000 , 85, 299-304	3	176
30	Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). <i>American Journal of Cardiology</i> , 2000 , 85, 1409-13	3	19
29	Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2000 , 86, 713-7	3	22
28	Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients?. <i>American Journal of Cardiology</i> , 2000 , 86, 908-12	3	4
27	Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. <i>American Journal of Cardiology</i> , 2000 , 86, 1235-7, A5	3	38

26	A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 9, 175-80	5.1	25
25	Association of unstable angina guideline care with improved survival. <i>Archives of Internal Medicine</i> , 2000 , 160, 1775-80		33
24	Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. <i>Circulation</i> , 2000 , 101, 239-43	16.7	218
23	High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. <i>Circulation</i> , 2000 , 101, 2690-5	16.7	64
22	Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina. <i>American Heart Journal</i> , 2000 , 139, 867-73	4.9	10
21	First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. <i>American Heart Journal</i> , 2000 , 140, 81-93	4.9	24
20	Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. <i>American Heart Journal</i> , 2000 , 140, 373-8	4.9	23
19	Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. <i>Clinica Chimica Acta</i> , 2000 , 298, 85-97	6.2	19
18	Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 2689-94	5.9	4
17	TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. <i>Circulation</i> , 2000 , 102, 2031-7	16.7	1067
16	Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. <i>Circulation</i> , 1999 , 99, 2720-32	16.7	559
15	Characteristics and prognosis of patients with suspected acute myocardial infarction and elevated MB relative index but normal total creatine kinase. <i>American Journal of Cardiology</i> , 1999 , 84, 957-62	3	14
14	A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. <i>Journal of the American College of Cardiology</i> , 1999 , 33, 1879-85	15.1	104
13	Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 974-82	15.1	114
12	Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1403-12	15.1	59
11	A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 49-52	5.1	6
10	Drug-Induced Thrombocytopenia: Is it a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 191-202	5.1	20
9	Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 6, 103-108	5.1	7

8	Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris. <i>American Journal of Cardiology</i> , 1998 , 81, 1182-6	3	46
7	Neural networks, logistic regression, and calibration: a reply. <i>Medical Decision Making</i> , 1998 , 18, 444-6	2.5	0
6	TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. <i>Circulation</i> , 1998 , 98, 2805-14	16.7	254
5	Neural network assessment of perioperative cardiac risk in vascular surgery patients. <i>Medical Decision Making</i> , 1998 , 18, 70-5	2.5	43
4	Elderly patients receive less aggressive medical and invasive management of unstable angina: potential impact of practice guidelines. <i>Archives of Internal Medicine</i> , 1998 , 158, 1113-20		86
3	Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 321-323	5.1	
2	Prognostic stratification of the patient after myocardial infarction in the thrombolytic era. <i>ACC Current Journal Review</i> , 1995 , 4, 36-39		
1	Facilitated Primary Percutaneous Coronary in Acute ST-Elevation Myocardial Infarction 118-132		